Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cancer Screening in HF
Cancer Screening in HF

Short Communication

Author(s): Sean Tan , Grace JX Chung , Jasmine Chan , et al Added: 1 year ago

Prevention & Chronic Conditions

Heart Failure
ESC HF 25: The TITRATE-HF Study
Author(s): Jasper J Brugts Added: 1 year ago
ESC HF 25 - TITRATE-HF shows 65% of patients with de novo heart failure receive guideline recommended medical therapy at 6 months in the Netherlands.Dr Jasper Brugts (Erasmus University Medical Centre, NL) joins us to discuss the outcomes from the TITRATE-HF study, which investigated adherence to the 2021 ESC guideline reccommendations for patients with heart failure with reduced ejecton fraction… View more

Guidelines & Statements

Heart Failure
AVR and ATTR Therapy Improve Survival in Dual Pathology
Added: 7 months ago Source:  Radcliffe Cardiology
New findings from a large, international registry suggest that in patients with the dual pathology of aortic stenosis and transthyretin-associated cardiac amyloidosis, a combination of aortic valve replacement and disease-specific medication offers the most significant survival benefit.¹ The study (NCT06129331) aimed to clarify the prognostic impact of these treatments in this increasingly… View more

Imaging & Diagnostics

Intervention
Beta-Blockers Cut MACE Risk Post-MI in Normal EF Patients
Added: 7 months ago Source:  Radcliffe Cardiology
The role of long-term beta-blocker therapy following a myocardial infarction (MI) in patients without heart failure remains a subject of clinical debate, particularly in the modern era of reperfusion and secondary prevention. The BETAMI–DANBLOCK trial sought to address this evidence gap by evaluating the efficacy of beta-blockers in this specific patient population.¹BETAMI–DANBLOCK was an open… View more

MI/ACS

Prevention & Chronic Conditions
Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy
Author(s): Long Peng , Tao Zeng , Enxi Quan , et al Added: 1 year ago

Cardiovascular Kidney Metabolic

Heart Failure
Targeting Obesity for Heart Failure
Author(s): Emily Morris , Oliver J Rider Added: 6 months ago

Cardiovascular Kidney Metabolic

Heart Failure
Phenotypes to Alerts in Heart Failure
Author(s): Added: 2 weeks ago
Prof Isabella Kardys (Erasmus MC University Medical Center, Rotterdam, NL) joins us to discuss how proteomic phenotyping, serial biomarkers and digital monitoring could enable more personalised, proactive heart failure care.Prof Kardys outlines work applying large-scale proteomics to HFpEF, where serial profiling of around 5,000 proteins in over 400 patients has revealed distinct subphenotypes… View more

Heart Failure
Worsening Heart Failure Case Study – Outpatient Setting
Author(s): Gianluigi Savarese Added: 1 year ago
Prof Gianluigi Savarese presents a second case study of a HFrEF patient with worsening heart failure symptoms in the outpatient clinic. The patient is already prescribed GDMT and a loop diuretic, Professor Savarese asks, ‘what are the next steps in managing this patient?’.Watch the second case by Gianluigi Savarese on Worsening Heart Failure – Inpatient Setting and a case from Javed Butler who… View more

Heart Failure
Gurleen Kaur headshot
Job title: Cardiovascular Medicine Fellow
Gurleen Kaur is a Cardiovascular Medicine Fellow at Brigham and Women's Hospital/Harvard Medical School in Boston. She earned her MD with Distinction in Research through the combined physician-scientist program at Rensselaer Polytechnic Institute and Albany Medical College, and completed her Internal Medicine residency at Brigham and Women's Hospital. Her prior research has focused on… View more
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 1 year ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Kidney Metabolic

Heart Failure